|
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 717.00 EUR | -4.81% |
|
-8.55% | +19.43% |
| 02:17pm | Sector Update: Health Care Stocks Advance Pre-Bell Monday | MT |
| 02:16pm | Argenx Shares Fall After Company Drops Trials for Eye-Disease Drug | DJ |
Company Valuation: argenx SE
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 11,400 | 16,291 | 19,269 | 20,293 | 36,221 | 46,096 | - | - |
| Change | - | 42.9% | 18.28% | 5.32% | 78.48% | 27.26% | - | - |
| Enterprise Value (EV) 1 | 9,781 | 14,186 | 18,515 | 17,352 | 32,974 | 43,120 | 41,597 | 39,825 |
| Change | - | 45.03% | 30.52% | -6.28% | 90.03% | 30.77% | -3.53% | -4.26% |
| P/E ratio | -20.8x | -43.8x | -28.3x | -72.1x | 48.9x | 48.9x | 29.4x | 21.8x |
| PBR | 8.44x | 7.1x | - | 5.39x | 7.4x | 7.97x | 6.24x | 4.77x |
| PEG | - | 1.1x | -0.4x | 1.2x | -0x | 1.9x | 0.4x | 0.6x |
| Capitalization / Revenue | 209x | 33.5x | 45.9x | 17.3x | 16.9x | 12.7x | 9.2x | 7.56x |
| EV / Revenue | 179x | 29.2x | 44.1x | 14.8x | 15.4x | 11.9x | 8.3x | 6.53x |
| EV / EBITDA | -23.6x | -45.7x | -31.9x | -59.8x | -8,314x | 42.8x | 23.6x | 16.3x |
| EV / EBIT | -23.4x | -45.1x | -27.3x | -44.2x | -1,600x | 44.1x | 22.5x | 15.8x |
| EV / FCF | -28.2x | -25.7x | -22.8x | -40.4x | -227x | 43.6x | 20.7x | 14.7x |
| FCF Yield | -3.55% | -3.9% | -4.39% | -2.47% | -0.44% | 2.29% | 4.82% | 6.8% |
| Dividend per Share 2 | - | - | - | - | - | - | - | 0.2168 |
| Rate of return | - | - | - | - | - | - | - | 0.03% |
| EPS 2 | -11.65 | -7.203 | -12.31 | -4.763 | 12.28 | 15.41 | 25.66 | 34.53 |
| Distribution rate | - | - | - | - | - | - | - | 0.63% |
| Net sales 1 | 54.53 | 486.3 | 419.9 | 1,171 | 2,143 | 3,619 | 5,010 | 6,094 |
| EBITDA 1 | -414.3 | -310.4 | -580.3 | -290.2 | -3.966 | 1,007 | 1,763 | 2,451 |
| EBIT 1 | -417.8 | -314.4 | -679.3 | -392.3 | -20.61 | 977.4 | 1,849 | 2,517 |
| Net income 1 | -528.9 | -368.1 | -669.1 | -272.3 | 792.7 | 989.9 | 1,757 | 2,240 |
| Net Debt 1 | -1,619 | -2,105 | -754.3 | -2,942 | -3,247 | -2,975 | -4,499 | -6,270 |
| Reference price 2 | 242.00 | 315.30 | 348.30 | 343.50 | 600.00 | 753.20 | 753.20 | 753.20 |
| Nbr of stocks (in thousands) | 47,108 | 51,668 | 55,324 | 59,079 | 60,368 | 61,200 | - | - |
| Announcement Date | 04/03/21 | 03/03/22 | 02/03/23 | 29/02/24 | 27/02/25 | - | - | - |
1EUR in Million2EUR
Estimates
P/E ratio, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 48.77x | 11.89x | 42.72x | -.--% | 54.11B | |
| -31.96x | 81.09x | -35.85x | -.--% | 42.02B | |
| 16.65x | 5.82x | 13.2x | 1.7% | 39.6B | |
| -23.83x | 3.27x | -8.94x | -.--% | 22.8B | |
| 17.26x | 4.24x | 11.37x | -.--% | 19.5B | |
| 28.14x | 5.53x | 15.33x | -.--% | 17.76B | |
| -513.74x | 29.73x | 701.05x | -.--% | 14.73B | |
| -13.59x | 170.75x | -26.62x | -.--% | 13.55B | |
| -192.75x | 45.87x | -186.28x | -.--% | 13.14B | |
| -57.96x | 13.09x | -55.48x | -.--% | 12.98B | |
| Average | -72.30x | 37.13x | 47.05x | 0.17% | 25.02B | |
| Weighted average by Cap. | -35.13x | 32.22x | 33.65x | 0.27% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Equities
- ARGX Stock
- Valuation argenx SE
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition